Cargando…
Short-term monotherapy with Liraglutide for weight management: A case study
BACKGROUND: Liraglutide 3 mg was approved by the FDA as an antiobesity drug. A recent study reported that short-term treatment with Liraglutide (20.0 ± 6.4 days) reduces body weight. CASE PRESENTATION: A 35-year-old male not having any medical illness was presented for medical weight-loss management...
Autor principal: | Almarshad, Feras |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559087/ https://www.ncbi.nlm.nih.gov/pubmed/31198765 http://dx.doi.org/10.4103/jfmpc.jfmpc_213_19 |
Ejemplares similares
-
Monotherapy with liraglutide – Points to be focussed
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2019) -
Short term monotherapy with GLP-1 receptor agonist liraglutide or PDE 4 inhibitor roflumilast is superior to metformin in weight loss in obese PCOS women: a pilot randomized study
por: Jensterle, Mojca, et al.
Publicado: (2015) -
Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013) -
Liraglutide for weight management: a critical review of the evidence
por: Mehta, A., et al.
Publicado: (2016) -
Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes
por: Mirabelli, Maria, et al.
Publicado: (2019)